1. Search Result
Search Result
Results for "

CoVs

" in MedChemExpress (MCE) Product Catalog:

1015

Inhibitors & Agonists

3

Screening Libraries

6

Fluorescent Dyes

5

Biochemical Assay Reagents

43

Peptides

50

Inhibitory Antibodies

104

Natural
Products

66

Isotope-Labeled Compounds

11

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137048
    PF-00835231
    4 Publications Verification

    SARS-CoV HIV HCV Infection
    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL pro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models .
    PF-00835231
  • HY-N1739
    Tectoquinone
    1 Publications Verification

    2-Methylanthraquinone

    Environmental Pollutants DNA Alkylator/Crosslinker SARS-CoV Virus Protease Infection Cancer
    Tectoquinone (2-Methylanthraquinone) is an inhibitor for SARS CoV-2 major protease (SARS CoV-2 Mpro). Tectoquinone exhibits anti-termite and antiviral activities .
    Tectoquinone
  • HY-P99604

    AZD-1061; COV2-2130

    SARS-CoV Infection
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
    Cilgavimab
  • HY-P99423
    Adintrevimab
    2 Publications Verification

    ADG 20

    SARS-CoV Infection
    Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
    Adintrevimab
  • HY-N1180

    SARS-CoV Keap1-Nrf2 Infection
    Tanshinlactone is a compound found in Salvia miltiorrhiza with anti-coronavirus (CoV) and anti-tumor activities. Tanshinlactone induces methuocytic cell death (methuosis) by activating the NRF2 pathway, and selectively kills ER +, HER2 +/EGFR + breast cancer cells. Tanshinlactone is applicable to research related to breast cancer and coronavirus infections .
    Tanshinlactone
  • HY-122872

    p38 MAPK Cancer
    MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein-protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM .
    MKK7-COV-9
  • HY-149535

    WU-04

    SARS-CoV Infection
    Iscartrelvir (WU-04) is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .
    Iscartrelvir
  • HY-143418

    SARS-CoV Infection
    SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .
    SARS-CoV-2-IN-17
  • HY-152005

    SARS-CoV Infection
    SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL pro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .
    SARS-CoV-2 3CLpro-IN-6
  • HY-135860

    Virus Protease SARS-CoV Infection
    SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively .
    SARS-CoV-2-IN-1
  • HY-N1739R

    2-Methylanthraquinone (Standard)

    Reference Standards SARS-CoV Virus Protease Infection
    Tectoquinone (Standard) is the analytical standard of Tectoquinone. This product is intended for research and analytical applications. Tectoquinone (2-Methylanthraquinone) is an inhibitor for SARS CoV-2 major protease (SARS CoV-2 Mpro). Tectoquinone exhibits anti-termite and antiviral activities .
    Tectoquinone (Standard)
  • HY-174373

    SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against SARS-CoV-2 infection with an IC50 of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2 .
    SARS-CoV-2-IN-113
  • HY-178480

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 main protease (M pro) inhibitor (IC50=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus .
    SARS-CoV-2 Mpro-IN-49
  • HY-146379

    DNA/RNA Synthesis SARS-CoV Infection
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
    SARS-CoV-2-IN-19
  • HY-159633

    SARS-CoV Infection
    PLpro-IN-5 (compound 21) is a PLPro protease inhibitor with an IC50 value of 91.14 nM. PLpro-IN-5 shows broad-spectrum antivirus, especially for SARS-CoV, MERS-CoV, SARS-CoV-2 .
    PLpro-IN-5
  • HY-157805

    PROTACs SARS-CoV Infection
    PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 M pro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC50 = 10.8 μM), HCoV-OC43 (EC50 = 1.6 μM) and HCoV-229E (EC50 = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC50 of 0.89 μM .
    PROTAC SARS-CoV-2 Mpro degrader-2
  • HY-P991445

    SARS-CoV Infection
    REGN3051 is a human IgG1 monoclonal antibody (mAb) targeting MERS CoV. REGN3051 reduces viral titers in the lungs of mice expressing human DPP4. REGN3051 decreases lung disease severity and viral replication in marmosets inoculated with MERS-CoV. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    REGN3051
  • HY-171781

    SARS-CoV Virus Protease Infection
    FL-166 is a SARS coronavirus main protease (Mpro) inhibitor (Ki: 40 nM). FL-166 exerts its inhibitory effect by targeting a cluster of serine residues near the active site of the protease. FL-166 can be used in the study of SARS-CoV .
    FL-166
  • HY-P10689

    SARS-CoV Infection
    NQK-A8 peptide is an immunodominant peptide of seasonal coronaviruses HKU1-CoV and OC43-CoV .
    NQK-A8 peptide
  • HY-162924

    SARS-CoV Infection
    SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 µM for SARS-CoV-1 replicon-based SRIPs and 1.47 µM for SARS-CoV-2 replicon-based SRIPs .
    SARS-CoV-IN-6
  • HY-155308

    SARS-CoV Infection
    SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
    SARS-CoV-2-IN-61
  • HY-150783

    SARS-CoV Infection
    SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .
    SARS-CoV-2-IN-24
  • HY-159477

    SARS-CoV Infection Inflammation/Immunology
    SARS-CoV-2-IN-92 (compound 11) inhibits SARS-CoV-2 variants (EC50 = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II .
    SARS-CoV-2-IN-92
  • HY-175712

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2 .
    SARS-CoV-2 Mpro-IN-47
  • HY-155119

    SARS-CoV Infection
    SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 21.4 μM .
    SARS-CoV-2-IN-54
  • HY-155121

    SARS-CoV Infection
    SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-56 has antiviral activity. SARS-CoV-2-IN-56 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.7 μM .
    SARS-CoV-2-IN-56
  • HY-170545

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-35 (compound 14) is a SARS-CoV-2 Mpro inhibitor. SARS-CoV-2 Mpro-IN-35 can be used for the research of SARS-CoV-2 virus .
    SARS-CoV-2 Mpro-IN-35
  • HY-162674

    SARS-CoV Infection
    MERS-CoV-IN-2 (compound 3c) is a MERS-CoV 3CLpro inhibitor (IC50=17nM). MERS-CoV-IN-2 inhibits the activity of the 3CLpro enzyme by binding to the active site of the enzyme, specifically the S4 subsite, thereby exhibiting antiviral activity against SARS-CoV-2 and MERS-CoV .
    MERS-CoV-IN-2
  • HY-162295

    SARS-CoV Infection
    SARS-CoV-2-IN-83 (compound C6E) has excellent activity against SARS CoV-2 spike protein .
    SARS-CoV-2-IN-83
  • HY-178772

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC50 of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC50 s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC50 : 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research .
    SARS-CoV-2 Mpro-IN-50
  • HY-149954

    SARS-CoV Infection
    SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1 .
    SARS-CoV-2-IN-39
  • HY-173514

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-42 (compound C5) is a potent SARS-CoV-2 Mpro inhibitor with an IC50 of 33.6 nM. SARS-CoV-2 Mpro-IN-42 can be used in the study of SARS-CoV-2 .
    SARS-CoV-2 Mpro-IN-42
  • HY-P10976

    SARS-CoV Infection
    Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .
    Spike Glycoprotein (1147-1162)
  • HY-170922

    SARS-CoV Infection
    SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC50 of 1.10 μM and significantly lower toxicity compared to Lapatinib (HY-50898). SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC50 of > 100 μM, with a selectivity index (SI) of >91 .
    SARS-CoV-2-IN-110
  • HY-173575

    SARS-CoV Virus Protease Infection
    SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC50 value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .
    SARS-CoV-2 3CLpro-IN-31
  • HY-173134

    SARS-CoV Infection
    SARS-CoV-2 RdRp-IN-1 (Compound PAP-2) is a potent SARS-CoV-2 RdRp inhibitor, with an EC50 of 1.11 μM. SARS-CoV-2 RdRp-IN-1 can bind directly to SARS-CoV-2 RdRp, fully resistance to the exoribonuclease (ExoN) and exhibit broad spectrum anti-CoV activities .
    SARS-CoV-2 RdRp-IN-1
  • HY-136606

    SARS-CoV Infection
    SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
    SARS-CoV MPro-IN-1
  • HY-168259

    SARS-CoV Infection
    PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM .
    PLpro-IN-8
  • HY-162790

    SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-95 (Compound 10) is an inhibitor for SARS-CoV-2 PLpro with an IC50 of 0.39 μM. SARS-CoV-2-IN-95 exhibits antiviral activity in mouse SARS-CoV-2-infected model .
    SARS-CoV-2-IN-95
  • HY-158687

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-18 (compound 84) is a potent SARS-CoV-2 Mpro inhibitor with the IC50 of 3.23 nM. SARS-CoV-2 Mpro-IN-18 can be used for study of anti-SARS-CoV-2 agent .
    SARS-CoV-2 Mpro-IN-18
  • HY-147805

    SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 3CLpro-IN-4
  • HY-147804

    SARS-CoV Bacterial Fungal Infection
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .
    SARS-CoV-2 3CLpro-IN-3
  • HY-163713

    SARS-CoV Infection
    SARS-CoV-2-IN-89 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-89 enhances IFN-I responses to SARS-CoV-2 infection in A549.hACE2 cells .
    SARS-CoV-2-IN-89
  • HY-156008

    SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M pro with an IC50 of 0.35 μM .
    SARS-CoV-2-IN-58
  • HY-151988

    SARS-CoV Infection
    SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .
    SARS-CoV-2-IN-36
  • HY-P3492

    SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
    SARS-CoV-2-IN-34
  • HY-175460

    SARS-CoV Infection
    SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research .
    SARS-CoV-2-IN-117
  • HY-178435

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-48 is a potent SARS-CoV-2 main protease inhibitor with an IC50 of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19 .
    SARS-CoV-2 Mpro-IN-48
  • HY-162154

    SARS-CoV Infection
    SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM .
    SARS-CoV-2-IN-75
  • HY-163857

    SARS-CoV Infection
    SARS-CoV-2-IN-91 (Compound 194) is an inhibitor for SARS-CoV 2 with an EC50 of 28.92 μM. SARS-CoV-2-IN-91 inhibits the viral -1 programmed ribosome frame shift (-1PRF) element, and thereby inhibits the replication of SARS-CoV 2 .
    SARS-CoV-2-IN-91

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: